Beta Bionics, Inc.
NASDAQ:BBNXMedical - Equipment & Services
+$0.42 today
- Market cap
- $644.70M
- Beta
- 3.39
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.50
Volume 1.38M
Average 0.99M
BBNX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Beta Bionics, Inc.NASDAQ: BBNX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $21.9M (cash outflow) fell 23.6% year over year, behind the -6.4% change in trailing-twelve-month net income. Sequentially, it rose 62.6% from the prior quarter. Over 3 fiscal years it compounded at +4.2% a year.
Context
- Net income amounted to 73.0% of revenue in FY2025, down 11.1 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 10 analysts of -$82.46M (+12.6%) for the fiscal year ending Dec 2026, a slowdown from the +33.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$21.9M+62.6% QoQ
- Last fiscal yearDec 2025
- -$73.2M+33.7% YoY
- LTMMar 2026
- -$66.44M-6.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -23.6% | +60.3% | +83.9 pp |
| 1 year | +33.7% | +12.6% | -21.0 pp |
| 3-year CAGR | +4.2% | +14.4% | +10.2 pp |
| 5-year CAGR | -18.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (73.2M) USD
- Year-over-year change
- -33.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (73.2M) | -33.7% |
| FY2024 | 2024-12-31 | (54.76M) | -24.2% |
| FY2023 | 2023-12-31 | (44.1M) | +31.9% |
| FY2022 | 2022-12-31 | (64.75M) | — |
Net Income vs competitors
How BBNX compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -6.4% is the 5th highest of 7, against a peer median of +31.9%.
- Net income amounts to 60.3% of revenue for BBNX, versus a peer median of 10.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 116.44B DKK | +4.8% | +22.6% | 35.3% | |
| LTM Jun 2026 | $999.7M USD | +74.9% | +34.8% | 20.1% | |
| LTM Jun 2026 | $375.3M USD | +59.0% | +277.3% | 12.3% | |
MMEDMiniMed Group, Inc. Common Stock | LTM Jul 2026 | $301M USD | — | +51.0% | 9.3% |
| LTM Mar 2026 | $110M USD | +489.6% | — | — | |
| LTM Mar 2026 | $94.55M USD | -48.6% | +29.3% | 9.2% | |
| LTM Mar 2026 | $66.44M USD | -6.4% | +4.2% | 60.3% | |
| LTM Mar 2026 | $23.91M USD | -179.4% | — | 6.6% | |
| Peer median (excluding BBNX) | — | +31.9% | +34.8% | 10.8% | |
Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (64.75M) | (44.1M) | (54.76M) | (73.2M) |
| Depreciation & Amortization | 2.09M | 2.09M | 2.28M | 2.88M |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.1M | 5.66M | 6.38M | 16.38M |
| Change in Working Capital | (2.79M) | (6.36M) | (12.15M) | (8.99M) |
| Accounts Receivables | 0 | (4.49M) | (7.62M) | (5.16M) |
| Inventory | 0 | (1.19M) | (11.44M) | (9.88M) |
| Accounts Payables | (77K) | 716K | 1.52M | 2.1M |
| Other Working Capital | (2.71M) | (682K) | 5.39M | 3.95M |
| Other Non-Cash Items | (854K) | 10.27M | 9.96M | 12.01M |
| Operating Cash Flow | (60.21M) | (32.45M) | (48.27M) | (50.93M) |
| Capital Expenditures | (772K) | (402K) | (3.4M) | (5.3M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (69.3M) | (72.13M) | (327.51M) |
| Sales of Investments | 0 | 0 | 72M | 170M |
| Other Investing Activities | 3K | (69.29M) | 50K | 0 |
| Investing Cash Flow | (769K) | (69.69M) | (3.48M) | (162.81M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 389K | 29K | 55.62M | 214.87M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 389K | 101.03M | 0 | 0 |
| Financing Cash Flow | 56.78M | 101.03M | 55.62M | 214.87M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (4.2M) | (1.11M) | 3.87M | 1.14M |
| Free Cash Flow | (60.98M) | (32.85M) | (51.67M) | (56.22M) |
Beta Bionics, Inc.
NASDAQ:BBNX
Intrinsic Alpha fair value
Locked
Current Price
$14.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.